Pharmaceutical

Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio

The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.

Jun 22, 2024 - 04:00
Tectonic bets on GPCR heart failure drug following reverse merger with Avrobio
The company has also raised $130.7m in a private placement, which along with Tectonics' previous cash reserves.
Read the original article

Tags:

Previous Article

Sarepta’s Elevidys secures US label expansion for DMD

Next Article

WHO warns of “harmful” fake Ozempic in circulation in Americas and Europe

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

BMS and Zai Lab’s Augtyro gains NMPA approval to treat NSCLC

BMS and Zai Lab’s Augtyro gains NMPA approval to treat ...

May 15, 2024

After 2022 interest rate hikes spook investors, pharma M&A to resurge in late 2023

After 2022 interest rate hikes spook investors, pharma ...

May 26, 2023

Researchers seek answers to racial disparities for prostate and breast cancer among people of African ancestry

Researchers seek answers to racial disparities for pros...

Aug 1, 2023